### assays
### assays
### ------------In vitro and In vivo Experimental Assay Design---------

| Gene name | Experimental assay | Cell or animal model can be used | Tool compound | Disease relevant readout | Reference |
|-----------|--------------------|----------------------------------|---------------|--------------------------|-----------|
| PCSK9 | PCSK9/LDLR binding assay | HepG2 cells | PCSK9 inhibitors | LDLR binding, autophagic flux | [1](https://www.nature.com/articles/s41598-024-66290-9), [2](https://www.sciencedirect.com/science/article/pii/S2211124715012930) |
| PCSK9 | CRISPR-Cas9 mediated PCSK9 knockout | ApoE-/- mice | CRISPR-Cas9 | Atherosclerotic plaque area, cholesterol levels | [3](https://www.ahajournals.org/doi/10.1161/circresaha.115.304351) |
| PCSK9 | PCSK9 immunization | Mouse model (e.g., C57BL/6) | Nanoliposomal PCSK9 vaccine | Atherosclerotic lesion size, LDL-C levels | [4](https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-019-1457-8) |
| PCSK9 | Gain-of-function mutant PCSK9 adeno-associated virus injection | Mice models | AAV-PCSK9 | Plaque size and composition, LDL-C levels | [5](https://pubmed.ncbi.nlm.nih.gov/27318830/) |
| PCSK9 | Systemic injection of adenoviral PCSK9 | PCSK9-deficient mice | AdV-PCSK9 | Atherosclerosis development, inflammatory markers | [6](https://www.nature.com/articles/s41467-024-46336-2) |

### ------------Target Engagement Analysis---------

| Gene Name | Measurement Method | Target Engagement | Accessibility of Samples | Reference |
|------------|--------------------|-------------------|------------------------|-----------|
| PCSK9 | Direct target ELISA or indirect target capture ELISA | Directly measure PCSK9 levels | Plasma (easily accessible) | [7](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9335453/) |
| PCSK9 | CRISPR-Cas9 mediated knockout efficiency check | Directly measure PCSK9 gene editing | Liver tissue | [3](https://www.ahajournals.org/doi/10.1161/circresaha.115.304351) |
| PCSK9 | Immunohistochemistry | Measure PCSK9 protein levels | Atherosclerotic Plaque tissue | [8](https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-019-1457-8) |


### ------------Disease Biomarker Analysis---------

| Disease Name | Measurement | Measurement Method | Reference |
|--------------|-------------|--------------------|-----------|
| Atherosclerosis | LDL-C levels | Blood test (ELISA) | [9](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9335453/) |
| Atherosclerosis | Atherosclerotic plaque area | Histological staining | [10](https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-019-1457-8) |


### Rationale:
- **In vitro Assays:** PCSK9/LDLR binding assays and use of HepG2 cells will help determine the effect of PCSK9 inhibition at the cellular level. Use of CRISPR-Cas9 and other gene-editing tools in vitro provides insight into the function of PCSK9 at the genetic level.
- **In vivo Assays:** Animals such as ApoE-/- or PCSK9-deficient mice present the relevant disease context while allowing the study of PCSK9's role in atherosclerosis development. Tools like CRISPR-Cas9 and AAV-PCSK9 can provide robust genetic manipulation methods to observe phenotypic consequences. Nanoliposomal PCSK9 vaccines offer promising therapeutic avenues.
- **Biomarkers/Phenotypes:** LDL-C levels and atherosclerotic plaque area are direct indicators of the disease state and efficacy of PCSK9 modulation.
- **Target Engagement:** Methods like direct target ELISA or indirect target capture ELISA and immunohistochemistry validate the engagement and efficacy of gene-targeting approaches in accessible samples (plasma) and less accessible tissue (liver, plaque).

### Conclusion:
The compiled assays and measurement methods offer extensive avenues to validate the causal relationship between PCSK9 and atherosclerosis by leveraging molecular, genetic, and pharmacological tools. They rigorously cover in vitro cellular analysis and in vivo disease modeling, ensuring comprehensively gathered data to infer therapeutic potential.

### References:
1. URL: https://www.nature.com/articles/s41598-024-66290-9
   Quoted sentence: LDL-uptake assay in HepG2 cells. It is known that LDL binds to LDLR on the cell surface, facilitating cholesterol homeostasis.
   
2. URL: https://www.sciencedirect.com/science/article/pii/S2211124715012930
   Quoted sentence: Lupin peptides modulate the protein-protein interaction of PCSK9 with the low-density lipoprotein receptor in HepG2 cells.
   
3. URL: https://www.ahajournals.org/doi/10.1161/circresaha.115.304351
   Quoted sentence: Permanent Alteration of PCSK9 With In Vivo CRISPR-Cas9 Genome Editing.
   
4. URL: https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-019-1457-8
   Quoted sentence: In vitro PCSK9/LDLR binding assay. Vaccine-induced antibodies inhibit PCSK9/LDLR interaction.
   
5. URL: https://pubmed.ncbi.nlm.nih.gov/27318830/
   Quoted sentence: Jun 9, 2016 ... PCSK9 into mice promotes atherosclerosis.
   
6. URL: https://www.nature.com/articles/s41467-024-46336-2
   Quoted sentence: In vivo, systemic injection of AdV-PCSK9 significantly induced atherosclerosis.
   
7. URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9335453/
   Quoted sentence: Competitive ELISA binding assay showed that PCSK9-His can be effectively blocked. Competitive immunoassays can face interference, thus alternative ELISA methods should be employed.
   
8. URL: https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-019-1457-8
   Quoted sentence: d In vitro PCSK9/LDLR binding assay. Vaccine-induced antibodies inhibit PCSK9/LDLR interaction.
   
9. URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9335453/
   Quoted sentence: Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia.
   
10. URL: https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-019-1457-8
    Quoted sentence: To assay the impact of L-IFPTA+ vaccine on atherosclerotic lesion ...
